Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 3
  5. Article
Volume 23, Issue 3
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

The frequent co-occurrence of major depressive disorder (MDD) and substance use disorders (SUDs) entails significant clinical challenges. Compared to patients with MDD alone, patients with MDD and SUD often show increased anhedonia, emotional blunting, and impaired cognitive function. These symptoms lead to an inability to control cravings, more substance use, increased relapse rates, and poor adherence to the treatment. This fosters a detrimental cycle leading to more severe depressive symptoms, functional impairment, and chronicity, culminating in heightened morbidity, mortality, and healthcare resource utilization. Data on antidepressant treatment of MDD-SUD patients are inconclusive and often conflicting because of a number of confounding factors in clinical trials or difficulty in dissecting the specific contributions of pharmacological psychological interventions in real-world studies. The patient's unique clinical features and specific SUD and MDD subtypes must be considered when choosing treatments. Ideally, drug treatment for MDD-SUD should act on both conditions and address core symptoms such as anhedonia, craving, and cognitive dysfunction while ensuring minimal emotional blunting, absence of drug interactions, and no addictive potential. This approach aims to address unmet needs and optimize the outcomes in a clinical population often underrepresented in treatment paradigms.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22666240827165327
2024-08-30
2025-01-18

  • From This Site

    /content/journals/cn/10.2174/1570159X22666240827165327
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Plana-RipollO. MuslinerK.L. DalsgaardS. MomenN.C. WeyeN. ChristensenM.K. AgerboE. IburgK.M. LaursenT.M. MortensenP.B. PedersenC.B. PetersenL.V. SantomauroD.F. VilhjálmssonB.J. WhitefordH.A. McGrathJ.J. Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study.World Psychiatry202019333934910.1002/wps.20802 32931098
     [Google Scholar]
  2. HuntG.E. MalhiG.S. ClearyM. LaiH.M.X. SitharthanT. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis.J. Affect. Disord.201620633134910.1016/j.jad.2016.07.011 27476137
     [Google Scholar]
  3. HuntG.E. LargeM.M. ClearyM. LaiH.M.X. SaundersJ.B. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis.Drug Alcohol Depend.201819123425810.1016/j.drugalcdep.2018.07.011 30153606
     [Google Scholar]
  4. MartinottiG. De RisioL. VanniniC. SchifanoF. PettorrusoM. Di GiannantonioM. Substance-related exogenous psychosis: a postmodern syndrome.CNS Spectr.2021261849110.1017/S1092852920001479 32580808
     [Google Scholar]
  5. World Health OrganizationDepression and Other Common Mental Disorders: Global Health Estimates.2017Available from: https://www.who.int/publications/i/item/depression-global-health-estimates
    [Google Scholar]
  6. HuntG.E. MalhiG.S. LaiH.M.X. ClearyM. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis.J. Affect. Disord.202026628830410.1016/j.jad.2020.01.141 32056890
     [Google Scholar]
  7. American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder2017Available from: https://psychiatryonline.org/doi/book/10.1176/appi.books.9781615371969
  8. BlancoC. AlegríaA.A. LiuS.M. Secades-VillaR. SugayaL. DaviesC. NunesE.V. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions.J. Clin. Psychiatry201273686587310.4088/JCP.10m06673 22480900
     [Google Scholar]
  9. HasegawaK. MukasaH. NakazawaY. KodamaH. NakamuraK. MiuraY. SatoT. Primary and secondary depression in alcoholism - clinical features and family history.Drug Alcohol Depend.199127327528110.1016/0376‑8716(91)90010‑V 1884669
     [Google Scholar]
  10. O’SullivanK. WhillansP. DalyM. CarrollB. ClareA. CooneyJ. A comparison of alcoholics with and without coexisting affective disorder.Br. J. Psychiatry1983143213313810.1192/bjp.143.2.133 6616115
     [Google Scholar]
  11. KahlerC.W. RamseyS.E. ReadJ.P. BrownR.A. McCradyB.S. BrownR.A. Substance-induced and independent major depressive disorder in treatment-seeking alcoholics: associations with dysfunctional attitudes and coping.J. Stud. Alcohol200263336337110.15288/jsa.2002.63.363 12086137
     [Google Scholar]
  12. NunesE.V. LiuX. SametS. MatseoaneK. HasinD. Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up.J. Clin. Psychiatry200667101561156710.4088/JCP.v67n1010 17107247
     [Google Scholar]
  13. RamseyS.E. KahlerC.W. ReadJ.P. StuartG.L. BrownR.A. Discriminating between substance-induced and independent depressive episodes in alcohol dependent patients.J. Stud. Alcohol200465567267610.15288/jsa.2004.65.672 15536779
     [Google Scholar]
  14. DavisL. UezatoA. NewellJ.M. FrazierE. Major depression and comorbid substance use disorders.Curr. Opin. Psychiatry2008211141810.1097/YCO.0b013e3282f32408 18281835
     [Google Scholar]
  15. SullivanL.E. FiellinD.A. O’ConnorP.G. The prevalence and impact of alcohol problems in major depression: A systematic review.Am. J. Med.2005118433034110.1016/j.amjmed.2005.01.007 15808128
     [Google Scholar]
  16. VolkowN.D. BlancoC. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention.World Psychiatry202322220322910.1002/wps.21073 37159360
     [Google Scholar]
  17. Di NicolaM. PepeM. PanaccioneI. MocciaL. DattoliL. MolinaroM. SaniG. JaniriL. McIntyreR.S. FiorilloA. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.CNS Spectr.2022271738110.1017/S109285292000173X 32772956
     [Google Scholar]
  18. Di NicolaM. PepeM. PanaccioneI. MocciaL. JaniriL. SaniG. Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: The role of extended-release trazodone.Curr. Neuropharmacol.202321112195220510.2174/1570159X21666230403080624 37013426
     [Google Scholar]
  19. LiJ. WangH. LiM. ShenQ. LiX. RongX. PengY. Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms-A bayesian network meta-analysis.CNS Neurosci. Ther.202026111185119710.1111/cns.13437 32686291
     [Google Scholar]
  20. KotzalidisG.D. LombardozziG. MatroneM. AmiciE. PerriniF. CuomoI. De FilippisS. Vortioxetine vs. Other antidepressants in patients with major depressive episode with or without substance use disorder.Curr. Neuropharmacol.202119122296230710.2174/1570159X19666210113150123 33441069
     [Google Scholar]
  21. PettinatiH.M. O’BrienC.P. DundonW.D. Current status of co-occurring mood and substance use disorders: a new therapeutic target.Am. J. Psychiatry20131701233010.1176/appi.ajp.2012.12010112 23223834
     [Google Scholar]
  22. PettinatiH.M. OslinD.W. KampmanK.M. DundonW.D. XieH. GallisT.L. DackisC.A. O’BrienC.P. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.Am. J. Psychiatry2010167666867510.1176/appi.ajp.2009.08060852 20231324
     [Google Scholar]
  23. FouldsJ.A. AdamsonS.J. BodenJ.M. WillimanJ.A. MulderR.T. Depression in patients with alcohol use disorders: Systematic review and meta-analysis of outcomes for independent and substance-induced disorders.J. Affect. Disord.2015185475910.1016/j.jad.2015.06.024 26143404
     [Google Scholar]
  24. World Health Organization (WHO) Global status report on alcohol and health 2018.GenevaWorld Health Organization2018
     [Google Scholar]
  25. TorrensM. Mestre-PintóJ.I. MontanariL. VicenteJ. Domingo-SalvanyA. Dual diagnosis: an European perspective.Adicciones20172913510.20882/adicciones.933 28170050
     [Google Scholar]
  26. GlantzM.D. BharatC. DegenhardtL. SampsonN.A. ScottK.M. LimC.C.W. Al-HamzawiA. AlonsoJ. AndradeL.H. CardosoG. De GirolamoG. GurejeO. HeY. HinkovH. KaramE.G. KaramG. Kovess-MasfetyV. LasebikanV. LeeS. LevinsonD. McGrathJ. Medina-MoraM.E. Mihaescu-PintiaC. MneimnehZ. MoskalewiczJ. Navarro-MateuF. Posada-VillaJ. RapseyC. StagnaroJ.C. TachimoriH. Ten HaveM. TintleN. TorresY. WilliamsD.R. ZivY. KesslerR.C. The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys.Addict. Behav.202010210612810.1016/j.addbeh.2019.106128 31865172
     [Google Scholar]
  27. LaiH.M.X. ClearyM. SitharthanT. HuntG.E. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis.Drug Alcohol Depend.201515411310.1016/j.drugalcdep.2015.05.031 26072219
     [Google Scholar]
  28. JalalH. BuchanichJ.M. RobertsM.S. BalmertL.C. ZhangK. BurkeD.S. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016.Science20183616408eaau118410.1126/science.aau1184 30237320
     [Google Scholar]
  29. McDonaldA.J. RoereckeM. MannR.E. Adolescent cannabis use and risk of mental health problems-the need for newer data.Addiction2019114101889189010.1111/add.14724 31256420
     [Google Scholar]
  30. VolkowN.D. BlancoC. The changing opioid crisis: development, challenges and opportunities.Mol. Psychiatry202126121823310.1038/s41380‑020‑0661‑4 32020048
     [Google Scholar]
  31. United Nations Office on Drugs and Crime,World drug report - drug market trends: Cannabis and opioids.2021Available from: https://www.unodc.org/unodc/data-and-analysis/wdr2021.html
    [Google Scholar]
  32. SantoT.Jr CampbellG. GisevN. Martino-BurkeD. WilsonJ. Colledge-FrisbyS. ClarkB. TranL.T. DegenhardtL. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis.Drug Alcohol Depend.202223810955110.1016/j.drugalcdep.2022.109551 35797876
     [Google Scholar]
  33. PeacockA. LeungJ. LarneyS. ColledgeS. HickmanM. RehmJ. GiovinoG.A. WestR. HallW. GriffithsP. AliR. GowingL. MarsdenJ. FerrariA.J. GrebelyJ. FarrellM. DegenhardtL. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report.Addiction2018113101905192610.1111/add.14234 29749059
     [Google Scholar]
  34. RavelliA. BijlR.V. van ZessenG. Comorbidity of psychiatric disorders in the Dutch population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS).Tijdschr. Psychiatr.199840531544
     [Google Scholar]
  35. GobbiG. AtkinT. ZytynskiT. WangS. AskariS. BoruffJ. WareM. MarmorsteinN. CiprianiA. DendukuriN. MayoN. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood.JAMA Psychiatry201976442643410.1001/jamapsychiatry.2018.4500 30758486
     [Google Scholar]
  36. LangloisC. PotvinS. KhullarA. TourjmanS.V. Down and high: Reflections regarding depression and cannabis.Front. Psychiatry20211262515810.3389/fpsyt.2021.625158 34054594
     [Google Scholar]
  37. GonçalvesJ. BaptistaS. SilvaA.P. Psychostimulants and brain dysfunction: A review of the relevant neurotoxic effects.Neuropharmacology20148713514910.1016/j.neuropharm.2014.01.006 24440369
     [Google Scholar]
  38. ElhwuegiA.S. Central monoamines and their role in major depression.Prog. Neuropsychopharmacol. Biol. Psychiatry200428343545110.1016/j.pnpbp.2003.11.018 15093950
     [Google Scholar]
  39. ConnerK.R. PinquartM. HolbrookA.P. Meta-analysis of depression and substance use and impairment among cocaine users.Drug Alcohol Depend.2008981-2132310.1016/j.drugalcdep.2008.05.005 18585871
     [Google Scholar]
  40. Glasner-EdwardsS. MooneyL.J. Marinelli-CaseyP. HillhouseM. AngA. RawsonR.A. Psychopathology in methamphetamine-dependent adults 3 years after treatment.Drug Alcohol Rev.2010291122010.1111/j.1465‑3362.2009.00081.x 20078677
     [Google Scholar]
  41. HellemT.L. LundbergK.J. RenshawP.F. A review of treatment options for co-occurring methamphetamine use disorders and depression.J. Addict. Nurs.2015261142310.1097/JAN.0000000000000058 25761159
     [Google Scholar]
  42. RounsavilleB.J. Treatment of cocaine dependence and depression.Biol. Psychiatry2004561080380910.1016/j.biopsych.2004.05.009 15556126
     [Google Scholar]
  43. GrantB.F. HarfordT.C. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey.Drug Alcohol Depend.199539319720610.1016/0376‑8716(95)01160‑4 8556968
     [Google Scholar]
  44. HasinD.S. GoodwinR.D. StinsonF.S. GrantB.F. Epidemiology of major depressive disorder.Arch. Gen. Psychiatry200562101097110610.1001/archpsyc.62.10.1097 16203955
     [Google Scholar]
  45. BodenJ.M. FergussonD.M. Alcohol and depression.Addiction2011106590691410.1111/j.1360‑0443.2010.03351.x 21382111
     [Google Scholar]
  46. MartinottiG. AlessiM.C. Di NataleC. SocialiA. CeciF. LucidiL. PicuttiE. Di CarloF. CorboM. VellanteF. FioriF. TourjanskyG. CatalanoG. CarentiM.L. IncertiC.C. BartolettiL. BarlatiS. RomeoV.M. VerrastroV. De GiorgioF. ValcheraA. SepedeG. CasellaP. PettorrusoM. di GiannantonioM. Psychopathological burden and quality of life in substance users during the COVID-19 lockdown period in Italy.Front. Psychiatry20201157224510.3389/fpsyt.2020.572245 33101086
     [Google Scholar]
  47. SchuckitM.A. Alcohol-use disorders.Lancet2009373966249250110.1016/S0140‑6736(09)60009‑X 19168210
     [Google Scholar]
  48. Di NicolaM. PepeM. ModicaM. LanzottiP. PanaccioneI. MocciaL. JaniriL. Mixed states in patients with substance and behavioral addictions.Psychiatr. Clin. North Am.202043112713710.1016/j.psc.2019.10.012 32008679
     [Google Scholar]
  49. UslanerJ. KalechsteinA. RichterT. LingW. NewtonT. Association of depressive symptoms during abstinence with the subjective high produced by cocaine.Am. J. Psychiatry199915691444144610.1176/ajp.156.9.1444 10484960
     [Google Scholar]
  50. DegenhardtL. HallW. LynskeyM. Exploring the association between cannabis use and depression.Addiction200398111493150410.1046/j.1360‑0443.2003.00437.x 14616175
     [Google Scholar]
  51. Lev-RanS. RoereckeM. Le FollB. GeorgeT.P. McKenzieK. RehmJ. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies.Psychol. Med.201444479781010.1017/S0033291713001438 23795762
     [Google Scholar]
  52. JefsenO.H. ErlangsenA. NordentoftM. HjorthøjC. Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder.JAMA Psychiatry202380880381010.1001/jamapsychiatry.2023.1256 37223912
     [Google Scholar]
  53. HanB. ComptonW.M. EinsteinE.B. VolkowN.D. Associations of suicidality trends with cannabis use as a function of sex and depression status.JAMA Netw. Open202146e211302510.1001/jamanetworkopen.2021.13025 34156452
     [Google Scholar]
  54. SharmaB. BrunerA. BarnettG. FishmanM. Opioid use disorders.Child Adolesc. Psychiatr. Clin. N. Am.201625347348710.1016/j.chc.2016.03.002 27338968
     [Google Scholar]
  55. MaremmaniA.G.I. PaciniM. MaremmaniI. What we have learned from the methadone maintenance treatment of dual disorder heroin use disorder patients.Int. J. Environ. Res. Public Health201916344710.3390/ijerph16030447 30717435
     [Google Scholar]
  56. TeessonM. MarelC. DarkeS. RossJ. SladeT. BurnsL. LynskeyM. MemedovicS. WhiteJ. MillsK.L. Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study.Addiction2015110698699310.1111/add.12860 25619110
     [Google Scholar]
  57. HserY.I. MooneyL.J. SaxonA.J. MiottoK. BellD.S. HuangD. Chronic pain among patients with opioid use disorder: Results from electronic health records data.J. Subst. Abuse Treat.201777263010.1016/j.jsat.2017.03.006 28476267
     [Google Scholar]
  58. MorinK.A. EiblJ.K. GauthierG. RushB. MushquashC. LightfootN.E. MarshD.C. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.Harm Reduct. J.20201715110.1186/s12954‑020‑00396‑x 32703310
     [Google Scholar]
  59. KampmanK. JarvisM. American society of addiction medicine (asam) national practice guideline for the use of medications in the treatment of addiction involving opioid use.J. Addict. Med.20159535836710.1097/ADM.0000000000000166 26406300
     [Google Scholar]
  60. XuK.Y. HuangV. WilliamsA.R. MartinC.E. BazaziA.R. GruczaR.A. Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims.Drug Alcohol Depend. Rep.2023910019510.1016/j.dadr.2023.100195 38023343
     [Google Scholar]
  61. HallN.Y. LeL. MajmudarI. MihalopoulosC. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective.Drug Alcohol Depend.202122110865110.1016/j.drugalcdep.2021.108651 33667783
     [Google Scholar]
  62. MojtabaiR. ChenL.Y. KaufmannC.N. CrumR.M. Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders.J. Subst. Abuse Treat.201446226827310.1016/j.jsat.2013.07.012 23992953
     [Google Scholar]
  63. DegenhardtL. GrebelyJ. StoneJ. HickmanM. VickermanP. MarshallB.D.L. BruneauJ. AlticeF.L. HendersonG. Rahimi-MovagharA. LarneyS. Global patterns of opioid use and dependence: harms to populations, interventions, and future action.Lancet2019394102081560157910.1016/S0140‑6736(19)32229‑9 31657732
     [Google Scholar]
  64. NosykB. MacNabY.C. SunH. FischerB. MarshD.C. SchechterM.T. AnisA.H. Proportional hazards frailty models for recurrent methadone maintenance treatment.Am. J. Epidemiol.2009170678379210.1093/aje/kwp186 19671835
     [Google Scholar]
  65. GelkopfM. WeizmanT. MelamedY. AdelsonM. BleichA. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.Isr. J. Psychiatry Relat. Sci.2006432126136 16910375
     [Google Scholar]
  66. AstalsM. DíazL. Domingo-SalvanyA. Martín-SantosR. BulbenaA. TorrensM. Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study.Int. J. Environ. Res. Public Health20096112822283210.3390/ijerph6112822 20049227
     [Google Scholar]
  67. FriesenE.L. KurdyakP. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.Drug Alcohol Depend.202021610824410.1016/j.drugalcdep.2020.108244 32861134
     [Google Scholar]
  68. VirtanenS. LagerbergT. KhemiriL. SuvisaariJ. LarssonH. LichtensteinP. ChangZ. LatvalaA. Association of selective serotonin re-uptake inhibitor (SSRI) treatment with acute substance misuse outcomes.Addiction2022117123424210.1111/add.15625 34185347
     [Google Scholar]
  69. BrennerP. BrandtL. LiG. DiBernardoA. BodénR. ReutforsJ. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study.Addiction2020115476877710.1111/add.14866 31656053
     [Google Scholar]
  70. CoughlinL.N. PfeifferP. GanoczyD. LinL.A. Quality of outpatient depression treatment in patients with comorbid substance use disorder.Am. J. Psychiatry2021178541442310.1176/appi.ajp.2020.20040454 33115247
     [Google Scholar]
  71. KohnR. SaxenaS. LevavI. SaracenoB. The treatment gap in mental health care.Bull. World Health Organ.20048211858866 15640922
     [Google Scholar]
  72. MerkxM.J.M. SchippersG.M. KoeterM.W.J. VuijkP.J. OudejansS.C.C. StamR.K. van den BrinkW. Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity.Addict. Behav.201136657057510.1016/j.addbeh.2010.12.021 21236585
     [Google Scholar]
  73. PepeM. Di NicolaM. PanaccioneI. FranzaR. De BerardisD. CibinM. JaniriL. SaniG. Impulsivity and alexithymia predict early versus subsequent relapse in patients with alcohol use disorder: A 1-year longitudinal study.Drug Alcohol Rev.202342236737210.1111/dar.13568 36269103
     [Google Scholar]
  74. HanB. OlfsonM. MojtabaiR. Depression care among adults with co-occurring major depressive episodes and substance use disorders in the United States.J. Psychiatr. Res.201791475610.1016/j.jpsychires.2017.02.026 28314128
     [Google Scholar]
  75. JordanN. SohnM.W. BartleB. ValensteinM. LeeY. LeeT.A. PfeifferP.N. KimH.M. ValensteinM. Association between chronic illness complexity and receipt of evidence-based depression care.Med. Care201452Suppl. 2S126S13110.1097/MLR.0000000000000036 24561751
     [Google Scholar]
  76. NunesE.V. LevinF.R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.JAMA2004291151887189610.1001/jama.291.15.1887 15100209
     [Google Scholar]
  77. DavisL.L. WisniewskiS.R. HowlandR.H. TrivediM.H. HusainM.M. FavaM. McGrathP.J. BalasubramaniG.K. WardenD. RushA.J. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.Drug Alcohol Depend.20101072-316117010.1016/j.drugalcdep.2009.10.003 19945804
     [Google Scholar]
  78. HesseM. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature.BMC Psychiatry200991610.1186/1471‑244X‑9‑6 19232121
     [Google Scholar]
  79. MuhonenL.H. LönnqvistJ. JuvaK. AlhoH. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.J. Clin. Psychiatry200869339239910.4088/JCP.v69n0308 18348597
     [Google Scholar]
  80. SchneiderB. Substance use disorders and risk for completed suicide.Arch. Suicide Res.200913430331610.1080/13811110903263191 19813108
     [Google Scholar]
  81. McHughR.K. WeissR.D. Alcohol use disorder and depressive disorders.Alcohol Res.201940110110.35946/arcr.v40.1.01
     [Google Scholar]
  82. SherL. StanleyB.H. Harkavy-FriedmanJ.M. CarballoJ.J. ArendtM. BrentD.A. SperlingD. LizardiD. MannJ.J. OquendoM.A. Depressed patients with co-occurring alcohol use disorders: a unique patient population.J. Clin. Psychiatry200869690791510.4088/JCP.v69n0604 18422397
     [Google Scholar]
  83. CartonL. PignonB. BaguetA. BenradiaI. RoelandtJ.L. VaivaG. ThomasP. AmadA. De TimaryP. NaassilaM. GeoffroyP.A. RollandB. Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.Drug Alcohol Depend.2018187404710.1016/j.drugalcdep.2018.02.009 29626745
     [Google Scholar]
  84. AbdellaouiA. SmitD.J.A. van den BrinkW. DenysD. VerweijK.J.H. Genomic relationships across psychiatric disorders including substance use disorders.Drug Alcohol Depend.202122010853510.1016/j.drugalcdep.2021.108535 33524898
     [Google Scholar]
  85. AndersenA.M. PietrzakR.H. KranzlerH.R. MaL. ZhouH. LiuX. KramerJ. KupermanS. EdenbergH.J. NurnbergerJ.I.Jr RiceJ.P. TischfieldJ.A. GoateA. ForoudT.M. MeyersJ.L. PorjeszB. DickD.M. HesselbrockV. BoerwinkleE. SouthwickS.M. KrystalJ.H. WeissmanM.M. LevinsonD.F. PotashJ.B. GelernterJ. HanS. Polygenic scores for major depressive disorder and risk of alcohol dependence.JAMA Psychiatry201774111153116010.1001/jamapsychiatry.2017.2269 28813562
     [Google Scholar]
  86. CrumR.M. GreenK.M. StuartE.A. La FlairL.N. KealhoferM. YoungA.S. KrawczykN. TormohlenK.N. StorrC.L. AlvanzoA.A.H. MojtabaiR. PacekL.R. CullenB.A. ReboussinB.A. Transitions through stages of alcohol involvement: The potential role of mood disorders.Drug Alcohol Depend.201818911612410.1016/j.drugalcdep.2018.02.027 29908411
     [Google Scholar]
  87. PavkovicB. ZaricM. MarkovicM. KlacarM. HuljicA. CaricicA. Double screening for dual disorder, alcoholism and depression.Psychiatry Res.201827048348910.1016/j.psychres.2018.10.013 30326431
     [Google Scholar]
  88. BoschlooL. van den BrinkW. PenninxB.W.J.H. WallM.M. HasinD.S. Alcohol-use disorder severity predicts first-incidence of depressive disorders.Psychol. Med.201242469570310.1017/S0033291711001681 21867593
     [Google Scholar]
  89. BrowerK.J. AldrichM.S. RobinsonE.A.R. ZuckerR.A. GredenJ.F. Insomnia, self-medication, and relapse to alcoholism.Am. J. Psychiatry2001158339940410.1176/appi.ajp.158.3.399 11229980
     [Google Scholar]
  90. ConroyD.A. Todd ArnedtJ. BrowerK.J. StrobbeS. ConsensF. HoffmannR. ArmitageR. HoffmannR.F. ArmitageR. Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking.Alcohol. Clin. Exp. Res.200630121992199910.1111/j.1530‑0277.2006.00245.x 17117964
     [Google Scholar]
  91. FosterJ.H. PetersT.J. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome.Alcohol. Clin. Exp. Res.19992361044105110.1111/j.1530‑0277.1999.tb04223.x 10397289
     [Google Scholar]
  92. ChakravortyS. GrandnerM.A. MavandadiS. PerlisM.L. SturgisE.B. OslinD.W. RahmanM. ApplebyD. AtwoodC.W.Jr CarskadonM.A. DingesD.F. Suicidal ideation in Veterans misusing alcohol: Relationships with insomnia symptoms and sleep duration.Addict. Behav.201439239940510.1016/j.addbeh.2013.09.022 24169371
     [Google Scholar]
  93. BaglioniC. BattaglieseG. FeigeB. SpiegelhalderK. NissenC. VoderholzerU. LombardoC. RiemannD. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies.J. Affect. Disord.20111351-3101910.1016/j.jad.2011.01.011 21300408
     [Google Scholar]
  94. ZhabenkoO. KrentzmanA.R. RobinsonE.A.R. BrowerK.J. ZuckerR.A. A longitudinal study of drinking and depression as predictors of insomnia in alcohol-dependent individuals.Subst. Use Misuse201348749550510.3109/10826084.2013.781182 23566203
     [Google Scholar]
  95. KollaB.P. SchneeklothT. BiernackaJ. MansukhaniM. GeskeJ. KarpyakV. Hall-FlavinD. LouikianovaL. FryeM.A. The course of sleep disturbances in early alcohol recovery: an observational cohort study.Am. J. Addict.2014231212610.1111/j.1521‑0391.2013.12056.x 24313237
     [Google Scholar]
  96. BrowerK.J. KrentzmanA. RobinsonE.A.R. Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals.Am. J. Addict.201120543544010.1111/j.1521‑0391.2011.00152.x 21838842
     [Google Scholar]
  97. GeoffroyP.A. LejoyeuxM. RollandB. Management of insomnia in alcohol use disorder.Expert Opin. Pharmacother.202021329730610.1080/14656566.2019.1705279 31899990
     [Google Scholar]
  98. DolsenE.A. HarveyA.G. Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994.Addiction201711261104111110.1111/add.13772 28127809
     [Google Scholar]
  99. KollaB.P. MansukhaniM.P. BiernackaJ. ChakravortyS. KarpyakV.M. Sleep disturbances in early alcohol recovery: Prevalence and associations with clinical characteristics and severity of alcohol consumption.Drug Alcohol Depend.202020610765510.1016/j.drugalcdep.2019.107655 31744670
     [Google Scholar]
  100. DestoopM. MorrensM. CoppensV. DomG. Addiction, anhedonia, and comorbid mood disorder. A narrative review.Front. Psychiatry20191031110.3389/fpsyt.2019.00311 31178763
     [Google Scholar]
  101. BauneB.T. BrignoneM. LarsenK.G. A Network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder.Int. J. Neuropsychopharmacol.20182129710710.1093/ijnp/pyx070 29053849
     [Google Scholar]
  102. ChristensenM.C. LoftH. McIntyreR.S. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.J. Affect. Disord.201822778779410.1016/j.jad.2017.11.081 29689693
     [Google Scholar]
  103. MartinottiG. CloningerC.R. JaniriL. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects.Am. J. Drug Alcohol Abuse200834217718310.1080/00952990701877078 18293234
     [Google Scholar]
  104. CooperJ.A. ArulpragasamA.R. TreadwayM.T. Anhedonia in depression: biological mechanisms and computational models.Curr. Opin. Behav. Sci.20182212813510.1016/j.cobeha.2018.01.024 29503842
     [Google Scholar]
  105. Claycomb ErwinM. CharakR. DurhamT.A. ArmourC. LvX. SouthwickS.M. ElhaiJ.D. PietrzakR.H. The 7-factor hybrid model of DSM-5 PTSD symptoms and alcohol consumption and consequences in a national sample of trauma-exposed veterans.J. Anxiety Disord.201751142110.1016/j.janxdis.2017.08.001 28843574
     [Google Scholar]
  106. Corral-FríasN.S. NikolovaY.S. MichalskiL.J. BarangerD.A.A. HaririA.R. BogdanR. Stress-related anhedonia is associated with ventral striatum reactivity to reward and transdiagnostic psychiatric symptomatology.Psychol. Med.201545122605261710.1017/S0033291715000525 25853627
     [Google Scholar]
  107. GarfieldJ.B.B. LubmanD.I. YücelM. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates.Aust. N. Z. J. Psychiatry2014481365110.1177/0004867413508455 24270310
     [Google Scholar]
  108. FawcettJ. ScheftnerW.A. FoggL. ClarkD.C. YoungM.A. HedekerD. GibbonsR. Time-related predictors of suicide in major affective disorder.Am. J. Psychiatry199014791189119410.1176/ajp.147.9.1189 2104515
     [Google Scholar]
  109. MorrisB.H. BylsmaL.M. RottenbergJ. Does emotion predict the course of major depressive disorder? A review of prospective studies.Br. J. Clin. Psychol.200948325527310.1348/014466508X396549 19187578
     [Google Scholar]
  110. UherR. PerlisR.H. HenigsbergN. ZobelA. RietschelM. MorsO. HauserJ. DernovsekM.Z. SoueryD. BajsM. MaierW. AitchisonK.J. FarmerA. McGuffinP. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.Psychol. Med.201242596798010.1017/S0033291711001905 21929846
     [Google Scholar]
  111. WinerE.S. NadorffM.R. EllisT.E. AllenJ.G. HerreraS. SalemT. Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample.Psychiatry Res.20142181-212412810.1016/j.psychres.2014.04.016 24774075
     [Google Scholar]
  112. PriceJ. ColeV. GoodwinG.M. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study.Br. J. Psychiatry2009195321121710.1192/bjp.bp.108.051110 19721109
     [Google Scholar]
  113. LallyN. NugentA.C. LuckenbaughD.A. AmeliR. RoiserJ.P. ZarateC.A. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.Transl. Psychiatry2014410e46910.1038/tp.2014.105 25313512
     [Google Scholar]
  114. ThomasR.K. BakerG. LindJ. DursunS. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.J. Psychopharmacol.201832101110111710.1177/0269881118793104 30182797
     [Google Scholar]
  115. PettorrusoM. GuidottiR. d’AndreaG. De RisioL. D’AndreaA. ChiappiniS. CarulloR. BarlatiS. ZanardiR. RossoG. De FilippisS. Di NicolaM. AndriolaI. MarcatiliM. NicolòG. MartiadisV. BassettiR. NuciforaD. De FazioP. RosenblatJ.D. ClericiM. Maria Dell’OssoB. VitaA. MarzettiL. SensiS.L. Di LorenzoG. McIntyreR.S. MartinottiG. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).Psychiatry Res.202332711537810.1016/j.psychres.2023.115378 37574600
     [Google Scholar]
  116. PepeM. BartolucciG. MarcelliI. PesaresiF. BrugnamiA. CasoR. FischettiA. GrisoniF. MazzaM. CamardeseG. Di NicolaM. SaniG. The patient’s perspective on the effects of intranasal esketamine in treatment-resistant depression.Brain Sci.20231310149410.3390/brainsci13101494 37891860
     [Google Scholar]
  117. ChiappiniS. d’AndreaG. De FilippisS. Di NicolaM. AndriolaI. BassettiR. BarlatiS. PettorrusoM. SensiS. ClericiM. Dell’OssoB. VitaA. MartinottiG. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.Eur. Neuropsychopharmacol.202374152110.1016/j.euroneuro.2023.04.011 37148637
     [Google Scholar]
  118. MartinottiG. VitaA. FagioliniA. MainaG. BertolinoA. Dell’OssoB. SiracusanoA. ClericiM. BellomoA. SaniG. d’AndreaG. ChiaieR.D. ConcaA. BarlatiS. Di LorenzoG. De FazioP. De FilippisS. NicolòG. RossoG. ValcheraA. NuciforaD. Di MauroS. BassettiR. MartiadisV. OlivolaM. BellettiS. AndriolaI. Di NicolaM. PettorrusoM. McIntyreR.S. di GiannantonioM. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).J. Affect. Disord.202231964665410.1016/j.jad.2022.09.043 36167246
     [Google Scholar]
  119. McIntyreR.S. LoftH. ChristensenM.C. Efficacy of vortioxetine on anhedonia: Results from a pooled analysis of short-term studies in patients with major depressive disorder.Neuropsychiatr. Dis. Treat.20211757558510.2147/NDT.S296451 33654400
     [Google Scholar]
  120. CaoB. ZhuJ. ZuckermanH. RosenblatJ.D. BrietzkeE. PanZ. SubramanieapillaiM. ParkC. LeeY. McIntyreR.S. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.Prog. Neuropsychopharmacol. Biol. Psychiatry20199210911710.1016/j.pnpbp.2019.01.002 30611836
     [Google Scholar]
  121. CaoB. ParkC. SubramaniapillaiM. LeeY. IacobucciM. MansurR.B. ZuckermanH. PhanL. McIntyreR.S. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder.Front. Psychiatry2019101710.3389/fpsyt.2019.00017 30766492
     [Google Scholar]
  122. PettorrusoM. SpagnoloP.A. LeggioL. JaniriL. Di GiannantonioM. GallimbertiL. BonciA. MartinottiG. Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: A pilot study.Brain Stimul.20181151195119710.1016/j.brs.2018.06.001 29885861
     [Google Scholar]
  123. MartinottiG. ReinaD. Di NicolaM. AndreoliS. TedeschiD. OrtolaniI. PozziG. IannoniE. D’IddioS. JaniriL. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial.Alcohol Alcohol.201045544945510.1093/alcalc/agq039 20595193
     [Google Scholar]
  124. MartinottiG. AndreoliS. ReinaD. Di NicolaM. OrtolaniI. TedeschiD. FanellaF. PozziG. IannoniE. D’IddioS. ProfL.J. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects.Prog. Neuropsychopharmacol. Biol. Psychiatry201135495395810.1016/j.pnpbp.2011.01.013 21256179
     [Google Scholar]
  125. SerrettiA. Anhedonia and depressive disorders.Clin. Psychopharmacol. Neurosci.202321340140910.9758/cpn.23.1086 37424409
     [Google Scholar]
  126. MattinglyG.W. NeckingO. SchmidtS.N. ReinesE. RenH. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.Curr. Med. Res. Opin.202339461361910.1080/03007995.2023.2178082 36884024
     [Google Scholar]
  127. SandellK. BornäsH. Functioning numbness instead of feelings as a direction: young adults’ experiences of antidepressant use.Sociology201751354355810.1177/0038038515591947
     [Google Scholar]
  128. FoxH.C. HongK.A. SinhaR. Difficulties in emotion regulation and impulse control in recently abstinent alcoholics compared with social drinkers.Addict. Behav.200833238839410.1016/j.addbeh.2007.10.002 18023295
     [Google Scholar]
  129. GoldsteinR.Z. VolkowN.D. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.Nat. Rev. Neurosci.2011121165266910.1038/nrn3119 22011681
     [Google Scholar]
  130. SawyerK.S. MalekiN. UrbanT. MarinkovicK. KarsonS. RuizS.M. HarrisG.J. Oscar-BermanM. Alcoholism gender differences in brain responsivity to emotional stimuli.eLife20198e4172310.7554/eLife.41723 31038125
     [Google Scholar]
  131. YipS.W. GrossJ.J. ChawlaM. MaS.S. ShiX.H. LiuL. YaoY.W. ZhuL. WorhunskyP.D. ZhangJ. Is neural processing of negative stimuli altered in addiction independent of drug effects? findings from drug-naïve youth with internet gaming disorder.Neuropsychopharmacology20184361364137210.1038/npp.2017.283 29154365
     [Google Scholar]
  132. GoodwinG.M. PriceJ. De BodinatC. LaredoJ. Emotional blunting with antidepressant treatments: A survey among depressed patients.J. Affect. Disord.2017221313510.1016/j.jad.2017.05.048 28628765
     [Google Scholar]
  133. ReadJ. CartwrightC. GibsonK. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants.Psychiatry Res.20142161677310.1016/j.psychres.2014.01.042 24534123
     [Google Scholar]
  134. BollingM.Y. KohlenbergR.J. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction.Psychother. Psychosom.200473638038510.1159/000080392 15479994
     [Google Scholar]
  135. FagioliniA. FloreaI. LoftH. ChristensenM.C. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment.J. Affect. Disord.202128347247910.1016/j.jad.2020.11.106 33516560
     [Google Scholar]
  136. GorwoodP. Neurobiological mechanisms of anhedonia.Dialogues Clin. Neurosci.200810329129910.31887/DCNS.2008.10.3/pgorwood 18979942
     [Google Scholar]
  137. BotvinickM. BraverT. Motivation and cognitive control: from behavior to neural mechanism.Annu. Rev. Psychol.20156618311310.1146/annurev‑psych‑010814‑015044 25251491
     [Google Scholar]
  138. BraverT.S. KrugM.K. ChiewK.S. KoolW. WestbrookJ.A. ClementN.J. AdcockR.A. BarchD.M. BotvinickM.M. CarverC.S. CoolsR. CustersR. DickinsonA. DweckC.S. FishbachA. GollwitzerP.M. HessT.M. IsaacowitzD.M. MatherM. MurayamaK. PessoaL. Samanez-LarkinG.R. SomervilleL.H. Mechanisms of motivation-cognition interaction: challenges and opportunities.Cogn. Affect. Behav. Neurosci.201414244347210.3758/s13415‑014‑0300‑0 24920442
     [Google Scholar]
  139. GrahekI. ShenhavA. MusslickS. KrebsR.M. KosterE.H.W. Motivation and cognitive control in depression.Neurosci. Biobehav. Rev.201910237138110.1016/j.neubiorev.2019.04.011 31047891
     [Google Scholar]
  140. McIntyreR.S. WoldeyohannesH.O. SoczynskaJ.K. MaruschakN.A. Wium-AndersenI.K. VinbergM. ChaD.S. LeeY. XiaoH.X. GallaugherL.A. DaleR.M. AlsuwaidanM.T. MansurR.B. MuzinaD.J. CarvalhoA.F. JerrellJ.M. KennedyS.H. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collab orative Project. CNS Spectr.,201621536236610.1017/S1092852915000747 26714651
     [Google Scholar]
  141. McIntyreR.S. LophavenS. OlsenC.K. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.Int. J. Neuropsychopharmacol.201417101557156710.1017/S1461145714000546 24787143
     [Google Scholar]
  142. McIntyreR.S. ChaD.S. SoczynskaJ.K. WoldeyohannesH.O. GallaugherL.A. KudlowP. AlsuwaidanM. BaskaranA. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.Depress. Anxiety201330651552710.1002/da.22063 23468126
     [Google Scholar]
  143. GoeldnerC. BallardT.M. KnoflachF. WichmannJ. GattiS. UmbrichtD. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.Neuropharmacology20136433734610.1016/j.neuropharm.2012.08.001 22992331
     [Google Scholar]
  144. MeluginP.R. NolanS.O. SicilianoC.A. Bidirectional causality between addiction and cognitive deficits.Int. Rev. Neurobiol.202115737140710.1016/bs.irn.2020.11.001 33648674
     [Google Scholar]
  145. 2016Available from: https://public4.pagefreezer.com/browse/FDA/04-03-2022T19:30/ https://www.fda.gov/advisory-committees/psychopharmacologic-drugs-advisory-committee/2016-meetingmaterials-psychopharmacologic-drugs-advisory-committee
  146. JaegerJ. BernsS. UzelacS. Davis-ConwayS. Neurocognitive deficits and disability in major depressive disorder.Psychiatry Res.20061451394810.1016/j.psychres.2005.11.011 17045658
     [Google Scholar]
  147. GreerT.L. KurianB.T. TrivediM.H. Defining and measuring functional recovery from depression.CNS Drugs201024426728410.2165/11530230‑000000000‑00000 20297853
     [Google Scholar]
  148. SubramaniapillaiM. MansurR.B. ZuckermanH. ParkC. LeeY. IacobucciM. CaoB. HoR. LinK. PhanL. McIntyreR.S. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.Compr. Psychiatry20199415211310.1016/j.comppsych.2019.07.006 31404802
     [Google Scholar]
  149. ChinC.N. ZainA. HemrungrojnS. UngE.K. KwansanitP. Au YongK.C. ChongM.S.W. InpaC. YenT.H. YeohB.B.D. TayL.K. BernardoC. LimL.C.C. YapC.H. FonesC. NayakA. NellemanL. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).Curr. Med. Res. Opin.201834111975198410.1080/03007995.2018.1477746 29768955
     [Google Scholar]
  150. ChokkaP. BougieJ. ProulxJ. TvistholmA.H. EttrupA. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.CNS Spectr.201924661662710.1017/S1092852919000786 30802419
     [Google Scholar]
  151. KatonaC. HansenT. OlsenC.K. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.Int. Clin. Psychopharmacol.201227421522310.1097/YIC.0b013e3283542457 22572889
     [Google Scholar]
  152. Basurte-VillamorI. VegaP. RonceroC. Martínez-RagaJ. Grau-LópezL. AguilarL. TorrensM. SzermanN. TorrensM. SzermanN. A feasibility study of patients with major depression and substance use disorders: Vortioxetine as maintenance treatment.Neuropsychiatr. Dis. Treat.20221896597610.2147/NDT.S358782 35547266
     [Google Scholar]
  153. DuranB. MalcoeL.H. SandersM. WaitzkinH. SkipperB. YagerJ. Child maltreatment prevalence and mental disorders outcomes among American Indian women in primary care.Child Abuse Negl.200428213114510.1016/j.chiabu.2003.06.005 15003398
     [Google Scholar]
  154. TucciA.M. Kerr-CorrêaF. Souza-FormigoniM.L.O. Childhood trauma in substance use disorder and depression: An analysis by gender among a Brazilian clinical sample.Child Abuse Negl.20103429510410.1016/j.chiabu.2009.07.001 20153055
     [Google Scholar]
  155. AndaR.F. FelittiV.J. BremnerJ.D. WalkerJ.D. WhitfieldC. PerryB.D. DubeS.R. GilesW.H. The enduring effects of abuse and related adverse experiences in childhood.Eur. Arch. Psychiatry Clin. Neurosci.2006256317418610.1007/s00406‑005‑0624‑4 16311898
     [Google Scholar]
  156. DubeS.R. AndaR.F. FelittiV.J. EdwardsV.J. CroftJ.B. Adverse childhood experiences and personal alcohol abuse as an adult.Addict. Behav.200227571372510.1016/S0306‑4603(01)00204‑0 12201379
     [Google Scholar]
  157. NelsonE.C. HeathA.C. LynskeyM.T. BucholzK.K. MaddenP.A.F. StathamD.J. MartinN.G. Childhood sexual abuse and risks for licit and illicit drug-related outcomes: a twin study.Psychol. Med.200636101473148310.1017/S0033291706008397 16854248
     [Google Scholar]
  158. ChapmanD.P. WhitfieldC.L. FelittiV.J. DubeS.R. EdwardsV.J. AndaR.F. Adverse childhood experiences and the risk of depressive disorders in adulthood.J. Affect. Disord.200482221722510.1016/j.jad.2003.12.013 15488250
     [Google Scholar]
  159. MolnarB.E. BukaS.L. KesslerR.C. Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey.Am. J. Public Health200191575376010.2105/AJPH.91.5.753 11344883
     [Google Scholar]
  160. AndaR.F. WhitfieldC.L. FelittiV.J. ChapmanD. EdwardsV.J. DubeS.R. WilliamsonD.F. Adverse childhood experiences, alcoholic parents, and later risk of alcoholism and depression.Psychiatr. Serv.20025381001100910.1176/appi.ps.53.8.1001 12161676
     [Google Scholar]
  161. Spatz WidomC. DuMontK. CzajaS.J. A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up.Arch. Gen. Psychiatry2007641495610.1001/archpsyc.64.1.49 17199054
     [Google Scholar]
  162. KippinT.E. SzumlinskiK.K. KapasovaZ. ReznerB. SeeR.E. Prenatal stress enhances responsiveness to cocaine.Neuropsychopharmacology200833476978210.1038/sj.npp.1301447 17487224
     [Google Scholar]
  163. Van WaesV. EnacheM. BertonO. VinnerE. LhermitteM. MaccariS. DarnaudéryM. Effect of prenatal stress on alcohol preference and sensitivity to chronic alcohol exposure in male rats.Psychopharmacology 2011214119720810.1007/s00213‑009‑1765‑3 20101392
     [Google Scholar]
  164. MarroccoJ. ReynaertM.L. GattaE. GabrielC. MocaërE. Di PriscoS. MeregaE. PittalugaA. NicolettiF. MaccariS. Morley-FletcherS. MairesseJ. The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders.J. Neurosci.20143462015202410.1523/JNEUROSCI.4131‑13.2014 24501344
     [Google Scholar]
  165. ØstergaardM.L.D. NordentoftM. HjorthøjC. Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personal.Addiction201711271250125910.1111/add.13788 28192643
     [Google Scholar]
  166. Di NicolaM. PepeM. MontanariS. MarcelliI. PanaccioneI. JaniriD. JaniriL. SaniG. Childhood sexual abuse and suicide attempts in patients with substance use disorders: The mediating role of emotion dysregulation.Child Abuse Negl.202415110673110.1016/j.chiabu.2024.106731 38507922
     [Google Scholar]
  167. BrittonP.C. StephensB. WuJ. KaneC. GallegosA. AshrafiounL. TuX. ConnerK.R. Comorbid depression and alcohol use disorders and prospective risk for suicide attempt in the year following inpatient hospitalization.J. Affect. Disord.201518715115510.1016/j.jad.2015.08.029 26339924
     [Google Scholar]
  168. RichardsJ.E. ShortreedS.M. SimonG.E. PenfoldR.B. GlassJ.E. ZiebellR. WilliamsE.C. ZiebellR. BradleyK.A. Short-term risk of suicide attempt associated with patterns of patient-reported alcohol use determined by routine AUDIT-C among adults receiving mental healthcare.Gen. Hosp. Psychiatry202062798610.1016/j.genhosppsych.2019.12.002 31874300
     [Google Scholar]
  169. SmithG.W. FarrellM. BuntingB.P. HoustonJ.E. ShevlinM. Patterns of polydrug use in Great Britain: Findings from a national household population survey.Drug Alcohol Depend.20111132-322222810.1016/j.drugalcdep.2010.08.010 20863629
     [Google Scholar]
  170. HarrellP.T. ManchaB.E. PetrasH. TrenzR.C. LatimerW.W. Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.Drug Alcohol Depend.2012122322022710.1016/j.drugalcdep.2011.10.001 22030276
     [Google Scholar]
  171. QuekL.H. ChanG.C.K. WhiteA. ConnorJ.P. BakerP.J. SaundersJ.B. KellyA.B. Concurrent and simultaneous polydrug use: latent class analysis of an Australian nationally representative sample of young adults.Front. Public Health201316110.3389/fpubh.2013.00061 24350230
     [Google Scholar]
  172. ConnorJ.P. GulloM.J. ChanG. YoungR.M. HallW.D. FeeneyG.F.X. Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs.Front. Psychiatry201347910.3389/fpsyt.2013.00079 23966956
     [Google Scholar]
  173. TrenzR.C. SchererM. DuncanA. HarrellP.T. MolekoA.G. LatimerW.W. Latent class analysis of polysubstance use, sexual risk behaviors, and infectious disease among South African drug users.Drug Alcohol Depend.2013132344144810.1016/j.drugalcdep.2013.03.004 23562370
     [Google Scholar]
  174. WhiteA. ChanG.C.K. QuekL.H. ConnorJ.P. SaundersJ.B. BakerP. BrackenridgeC. KellyA.B. The topography of multiple drug use among adolescent Australians: Findings from the national drug strategy household survey.Addict. Behav.20133842068207310.1016/j.addbeh.2013.01.001 23403274
     [Google Scholar]
  175. HeddenS.L. MartinsS.S. MalcolmR.J. FloydL. CavanaughC.E. LatimerW.W. Patterns of illegal drug use among an adult alcohol dependent population: Results from the national survey on drug use and health.Drug Alcohol Depend.20101062-311912510.1016/j.drugalcdep.2009.08.002 19758770
     [Google Scholar]
  176. BhallaI. P. StefanovicsE. A. RosenheckR. A. Clinical epidemiology of single versus multiple substance use disorders: Polysubstance use disorder.Med. Care201755Suppl 9 Suppl 2S24S3210.1097/MLR.0000000000000731
     [Google Scholar]
  177. BuntingA.M. ShearerR. Linden-CarmichaelA.N. WilliamsA.R. ComerS.D. CerdáM. LorvickJ. Are you thinking what I’m thinking? Defining what we mean by “polysubstance use.”.Am. J. Drug Alcohol Abuse20245011710.1080/00952990.2023.2248360 37734160
     [Google Scholar]
  178. VolkowN.D. WangG-J. FowlerJ.S. TomasiD. Addiction circuitry in the human brain.FOCUS201513334135010.1176/appi.focus.130306
     [Google Scholar]
  179. PetersK.Z. CheerJ.F. ToniniR. Modulating the neuromodulators: Dopamine, serotonin, and the endocannabinoid system.Trends Neurosci.202144646447710.1016/j.tins.2021.02.001 33674134
     [Google Scholar]
  180. DingZ.M. OsterS.M. HallS.R. EnglemanE.A. HauserS.R. McBrideW.J. RoddZ.A. The stimulating effects of ethanol on ventral tegmental area dopamine neurons projecting to the ventral pallidum and medial prefrontal cortex in female Wistar rats: regional difference and involvement of serotonin-3 receptors.Psychopharmacology 2011216224525510.1007/s00213‑011‑2208‑5 21340473
     [Google Scholar]
  181. NocjarC. RothB.L. PehekE.A. Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group.Neuroscience2002111116317610.1016/S0306‑4522(01)00593‑0 11955720
     [Google Scholar]
  182. MurnaneK.S. WinschelJ. SchmidtK.T. StewartL.M. RoseS.J. ChengK. RiceK.C. HowellL.L. Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates.J. Neurosci.20133333133671337410.1523/JNEUROSCI.1437‑13.2013 23946394
     [Google Scholar]
  183. HowellL.L. CunninghamK.A. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.Pharmacol. Rev.201567117619710.1124/pr.114.009514 25505168
     [Google Scholar]
  184. GottiC. GuiducciS. TedescoV. CorbioliS. ZanettiL. MorettiM. ZanardiA. RimondiniR. MugnainiM. ClementiF. ChiamuleraC. ZoliM. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.J. Neurosci.201030155311532510.1523/JNEUROSCI.5095‑09.2010 20392953
     [Google Scholar]
  185. HeiligM. GoldmanD. BerrettiniW. O’BrienC.P. Pharmacogenetic approaches to the treatment of alcohol addiction.Nat. Rev. Neurosci.2011121167068410.1038/nrn3110 22011682
     [Google Scholar]
  186. XiaoC. ZhouC. JiangJ. YinC. Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence.Acta Pharmacol. Sin.20204111910.1038/s41401‑019‑0299‑4 31554960
     [Google Scholar]
  187. CheerJ.F. MarsdenC.A. KendallD.A. MasonR. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study.Neuroscience200099466166710.1016/S0306‑4522(00)00241‑4 10974429
     [Google Scholar]
  188. RiegelA.C. LupicaC.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area.J. Neurosci.20042449110701107810.1523/JNEUROSCI.3695‑04.2004 15590923
     [Google Scholar]
  189. DarcqE. KiefferB.L. Opioid receptors: drivers to addiction?Nat. Rev. Neurosci.201819849951410.1038/s41583‑018‑0028‑x 29934561
     [Google Scholar]
  190. Lemos DuarteM. DeviL.A. Post-translational modifications of opioid receptors.Trends Neurosci.202043641743210.1016/j.tins.2020.03.011 32459993
     [Google Scholar]
  191. WalkerB.M. KoobG.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.Neuropsychopharmacology200833364365210.1038/sj.npp.1301438 17473837
     [Google Scholar]
  192. ClerkeJ. Preston-FerrerP. ZouridisI.S. TissotA. BattiL. VoigtF.F. PagèsS. BurgalossiA. MameliM. Output-specific adaptation of habenula-midbrain excitatory synapses during cocaine withdrawal.Front. Synaptic Neurosci.20211364313810.3389/fnsyn.2021.643138 33867967
     [Google Scholar]
  193. VolkowN.D. MoralesM. The Brain on Drugs: From Reward to Addiction.Cell2015162471272510.1016/j.cell.2015.07.046 26276628
     [Google Scholar]
  194. KoobG.F. VolkowN.D. Neurobiology of addiction: A neurocircuitry analysis.Lancet Psychiatry20163876077310.1016/S2215‑0366(16)00104‑8 27475769
     [Google Scholar]
  195. MoussawiK. PacchioniA. MoranM. OliveM.F. GassJ.T. LavinA. KalivasP.W. N-Acetylcysteine reverses cocaine-induced metaplasticity.Nat. Neurosci.200912218218910.1038/nn.2250 19136971
     [Google Scholar]
  196. BobadillaA.C. HeinsbroekJ.A. GipsonC.D. GriffinW.C. FowlerC.D. KennyP.J. KalivasP.W. Corticostriatal plasticity, neuronal ensembles, and regulation of drug-seeking behavior.,Prog. Brain Res.20172359311210.1016/bs.pbr.2017.07.013 29054293
     [Google Scholar]
  197. VenturaR. MorroneC. Puglisi-AllegraS. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli.Proc. Natl. Acad. Sci. USA2007104125181518610.1073/pnas.0610178104 17360372
     [Google Scholar]
  198. Puglisi-AllegraS. VenturaR. Prefrontal/accumbal catecholamine system processes emotionally driven attribution of motivational salience.Rev. Neurosci.2012235-650952610.1515/revneuro‑2012‑0076 23159865
     [Google Scholar]
  199. Puglisi-AllegraS. VenturaR. Prefrontal/accumbal catecholamine system processes high motivational salience.Front. Behav. Neurosci.201263110.3389/fnbeh.2012.00031 22754514
     [Google Scholar]
  200. CuomoA. BalleriniA. BruniA.C. DecinaP. Di SciascioG. FiorentiniA. ScaglioneF. VampiniC. FagioliniA. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.Riv. Psichiatr.201954413714910.1708/3202.31796 31379379
     [Google Scholar]
  201. European Medicines Agency Brintellix (vortioxetine) Summary of Product Characteristics,Available from: https://www.ema.europa.eu/en/documents/product-information/brintellix-epar-product-information_en.pdf
  202. Bang-AndersenB. RuhlandT. JørgensenM. SmithG. FrederiksenK. JensenK.G. ZhongH. NielsenS.M. HoggS. MørkA. StensbølT.B. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.J. Med. Chem.20115493206322110.1021/jm101459g 21486038
     [Google Scholar]
  203. LovingerD.M. WhiteG. Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons.Mol. Pharmacol.1991402263270 1715016
     [Google Scholar]
  204. European Medicines Agency Spravato (esketamine) Summary of Product Characteristics, Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf
  205. ZanosP. GouldT.D. Mechanisms of ketamine action as an antidepressant.Mol. Psychiatry201823480181110.1038/mp.2017.255 29532791
     [Google Scholar]
  206. ZhangM.W.B. HoR.C.M. Controversies of the effect of ketamine on cognition.Front. Psychiatry201674710.3389/fpsyt.2016.00047 27065891
     [Google Scholar]
  207. ZhangM.W.B. HongY.X. HusainS.F. HarrisK.M. HoR.C.M. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015.PLoS One2017123e017320210.1371/journal.pone.0173202 28257514
     [Google Scholar]
  208. RiggsP.D. DaviesR.D. A clinical approach to integrating treatment for adolescent depression and substance abuse.J. Am. Acad. Child Adolesc. Psychiatry200241101253125510.1097/00004583‑200210000‑00016 12364848
     [Google Scholar]
  209. KellyT.M. DaleyD.C. Integrated treatment of substance use and psychiatric disorders.Soc. Work Public Health2013283-438840610.1080/19371918.2013.774673 23731427
     [Google Scholar]
  210. SolhkhahR. WilensT.E. DalyJ. PrinceJ.B. PattenS.L.V. BiedermanJ. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders.J. Child Adolesc. Psychopharmacol.200515577778610.1089/cap.2005.15.777 16262594
     [Google Scholar]
  211. TorrensM. FonsecaF. MateuG. FarréM. Efficacy of antidepressants in substance use disorders with and without comorbid depression.Drug Alcohol Depend.200578112210.1016/j.drugalcdep.2004.09.004 15769553
     [Google Scholar]
  212. TorrensM. Tirado-MuñozJ. FonsecaF. FarréM. González-PintoA. ArrojoM. BernardoM. ArranzB. GarrigaM. SáizP.A. FlórezG. GoikoleaJ.M. ZorrillaI. CunillR. CastellsX. BecoñaE. LópezA. SanL. Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder.Adicciones202234212814110.20882/adicciones.1559 33768269
     [Google Scholar]
  213. PaniP.P. TroguE. VecchiS. AmatoL. Antidepressants for cocaine dependence and problematic cocaine use.Cochrane Libr.2011CD00295012CD00295010.1002/14651858.CD002950.pub3 22161371
     [Google Scholar]
  214. ZhouX. QinB. Del GiovaneC. PanJ. GentileS. LiuY. LanX. YuJ. XieP. Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis.Addiction20151101384810.1111/add.12698 25098732
     [Google Scholar]
  215. CorneliusJ.R. ClarkD.B. BuksteinO.G. BirmaherB. SalloumI.M. BrownS.A. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: A review.Addict. Behav.20053091824183310.1016/j.addbeh.2005.07.007 16102905
     [Google Scholar]
  216. SatoT. Interventions for co-occurring cannabis use and depression.Cureus2022148e2763210.7759/cureus.27632 36072196
     [Google Scholar]
  217. DeadyM. TeessonM. Kay-LambkinF. Treatments for co-occurring depression and substance use in young people: a systematic review.Curr. Drug Abuse Rev.20147131710.2174/1874473707666141015220608 25323123
     [Google Scholar]
  218. MurthyP. MahadevanJ. ChandP.K. Treatment of substance use disorders with co-occurring severe mental health disorders.Curr. Opin. Psychiatry201932429329910.1097/YCO.0000000000000510 31157674
     [Google Scholar]
  219. HassanA.N. HoweA.S. SamokhvalovA.V. Le FollB. GeorgeT.P. GeorgeT.P. ZawertailoL. Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis.Am. J. Addict.201726655156310.1111/ajad.12581 28675762
     [Google Scholar]
  220. FluyauD. MitraP. JainA. KailasamV.K. PierreC.G. Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.Eur. J. Clin. Pharmacol.202278693194210.1007/s00228‑022‑03303‑4 35246699
     [Google Scholar]
  221. NunesE.V. QuitkinF. BradyR. Post-KoenigT. Antidepressant treatment in methadone maintenance patients.J. Addict. Dis.1995133132410.1300/J069v13n03_02 7734456
     [Google Scholar]
  222. NunesE.V. SullivanM.A. LevinF.R. Treatment of depression in patients with opiate dependence.Biol. Psychiatry2004561079380210.1016/j.biopsych.2004.06.037 15556125
     [Google Scholar]
  223. PedrelliP. IovienoN. VitaliM. TedeschiniE. BentleyK.H. PapakostasG.I. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.J. Clin. Psychopharmacol.201131558258610.1097/JCP.0b013e31822c0adf 21869696
     [Google Scholar]
  224. PaniP.P. VaccaR. TroguE. AmatoL. DavoliM. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence.Cochrane Libr.2010CD0083739CD00837310.1002/14651858.CD008373.pub2 20824876
     [Google Scholar]
  225. SteinM.D. HermanD.S. KettavongM. CioeP.A. FriedmannP.D. TelliogluT. AndersonB.J. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.J. Subst. Abuse Treat.201039215716610.1016/j.jsat.2010.05.014 20598836
     [Google Scholar]
  226. ZhangK. JonesC. M. ComptonW. M. GuyG. P. EvansM. E. VolkowN. D. Association between receipt of antidepressants and retention in buprenorphine treatment for opioid use disorder: A population-based retrospective cohort study. J. Clin. Psychiatry,202283321m1400110.4088/JCP.21m14001
     [Google Scholar]
  227. NamchukA.B. LuckiI. BrowneC.A. Buprenorphine as a treatment for major depression and opioid use disorder.Advances in Drug and Alcohol Research202221025410.3389/adar.2022.10254 36177442
     [Google Scholar]
  228. PetryN.M. Contingency management: what it is and why psychiatrists should want to use it.Psychiatrist201135516116310.1192/pb.bp.110.031831 22558006
     [Google Scholar]
  229. KellyT.M. DaleyD.C. DouaihyA.B. Contingency management for patients with dual disorders in intensive outpatient treatment for addiction.J. Dual Diagn.201410310811710.1080/15504263.2014.924772 25392284
     [Google Scholar]
  230. CarrollK.M. RounsavilleB.J. A perfect platform: combining contingency management with medications for drug abuse.Am. J. Drug Alcohol Abuse200733334336510.1080/00952990701301319 17613963
     [Google Scholar]
  231. KostenT. OlivetoA. FeingoldA. PolingJ. SevarinoK. McCance-KatzE. StineS. GonzalezG. GonsaiK. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.Drug Alcohol Depend.200370331532510.1016/S0376‑8716(03)00032‑2 12757969
     [Google Scholar]
  232. PolingJ. OlivetoA. PetryN. SofuogluM. GonsaiK. GonzalezG. MartellB. KostenT.R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.Arch. Gen. Psychiatry200663221922810.1001/archpsyc.63.2.219 16461866
     [Google Scholar]
  233. WorrellS.D. GouldT.J. Therapeutic potential of ketamine for alcohol use disorder.Neurosci. Biobehav. Rev.202112657358910.1016/j.neubiorev.2021.05.006 33989669
     [Google Scholar]
  234. FornaroM. De BerardisD. AnastasiaA. FuscoA. Novel psychopharmacology for depressive disorders.In: Adv. Exp. Med. Biol.SingaporeSpringer2021Vol. 130544946110.1007/978‑981‑33‑6044‑0_22
     [Google Scholar]
  235. YoonG. PetrakisI.L. KrystalJ.H. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder.JAMA Psychiatry201976333733810.1001/jamapsychiatry.2018.3990 30624551
     [Google Scholar]
  236. De BerardisD. FornaroM. AnastasiaA. VellanteF. OlivieriL. RapiniG. SerroniN. OrsoliniL. ValcheraA. CaranoA. TomasettiC. VentriglioA. BustiniM. PompiliM. SerafiniG. PernaG. IasevoliF. MartinottiG. Di GiannantonioM. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study.Br. J. Psychiatry202042331732110.1590/1516‑4446‑2019‑0690 32159712
     [Google Scholar]
  237. De CarloV. VismaraM. GranciniB. BenattiB. BosiM.F. ColomboA. ViganòC.A. Dell’OssoB. MazzaM.G. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study.Hum. Psychopharmacol.2020355e275010.1002/hup.2750 32662933
     [Google Scholar]
  238. PettorrusoM. di GiannantonioM. De RisioL. MartinottiG. KoobG.F. A light in the darkness: Repetitive transcranial magnetic stimulation (rTMS) to treat the hedonic dysregulation of addiction.J. Addict. Med.202014427227410.1097/ADM.0000000000000575 31725426
     [Google Scholar]
  239. MartinottiG. PettorrusoM. MontemitroC. SpagnoloP.A. Acuti MartellucciC. Di CarloF. FanellaF. di GiannantonioM. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial.Prog. Neuropsychopharmacol. Biol. Psychiatry202211611051310.1016/j.pnpbp.2022.110513 35074451
     [Google Scholar]
  240. National Institute for Health and Care Excellence (NICE) National Collaborating Centre for Mental Health (Great Britain), National Institute for Health, & Clinical Excellence (Great Britain). Alcohol use disorders: The NICE guideline on the diagnosis, assessment and management of harmful drinking and alcohol dependence,2011Available from: https://www.nice.org.uk/guidance/cg115
    [Google Scholar]
  241. IovienoN. TedeschiniE. BentleyK.H. EvinsA.E. PapakostasG.I. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.J. Clin. Psychiatry20117281144115110.4088/JCP.10m06217 21536001
     [Google Scholar]
  242. KhouzamH.R. A review of trazodone use in psychiatric and medical conditions.Postgrad. Med.2017129114014810.1080/00325481.2017.1249265 27744763
     [Google Scholar]
  243. AgabioR. TroguE. PaniP.P. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.Cochrane Database Syst. Rev.20184CD00858110.1002/14651858.CD008581.pub2
     [Google Scholar]
  244. HillemacherT. FrielingH. Pharmacotherapeutic options for co-morbid depression and alcohol dependence.Expert Opin. Pharmacother.201920554756910.1080/14656566.2018.1561870 30602322
     [Google Scholar]
  245. StokesP.R.A. JokinenT. AmawiS. QureshiM. HusainM.I. YathamL.N. StrangJ. YoungA.H. VoonV. NuttD.J. ErritzoeD. HowesO. LeechR. MehtaM. SelvarajS. YoungA.H. NewhouseS. GrasbyP. Sagnay de la BastidaV. Merlo PichE. MurphyA.L. MorrisonP.D. Pharmacological treatment of mood disorders and comorbid addictions: a systematic review and meta-analysis: Traitement pharmacologique des troubles de l’humeur et des dépendances comorbides: une revue systématique et une méta-analyse.Can. J. Psychiatry2020651174976910.1177/0706743720915420 32302221
     [Google Scholar]
  246. GrantS. AzharG. HanE. BoothM. MotalaA. LarkinJ. HempelS. DassN. SajjadR. RajputK. Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis.PLoS Med.20211810e100382210.1371/journal.pmed.1003822 34624018
     [Google Scholar]
  247. US Department of Veterans Affairs US Department of Defense VA/DoD Clinical Practice Guideline for the Management of Substance use Disorders.2021Available from: https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf
    [Google Scholar]
  248. VinnikovaM.A. SevertsevV.V. KomarovS.D. VdovinA.S. Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study.Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova202112112576210.17116/jnevro202112112157 35041313
     [Google Scholar]
  249. ZastrozhinM. SkryabinV. SmirnovV. ZastrozhinaA. GrishinaE. RyzhikovaK. BureI. GolovinskiiP. KoporovS. BryunE. SychevD. Effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine in major depressive disorder.Am. J. Ther.2022291e26e3310.1097/MJT.0000000000001388 34117140
     [Google Scholar]
  250. ZastrozhinM.S. SkryabinV.Y. PetukhovA.E. TorradoM.V. PankratenkoE.P. ZastrozhinaA.K. GrishinaE.A. RyzhikovaK.A. ShipitsynV.V. BryunE.A. SychevD.A. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.Pharmacogenomics J.202121443543910.1038/s41397‑021‑00219‑7 33608663
     [Google Scholar]
  251. ZastrozhinM.S. SkryabinV.Y. PetukhovA.E. PankratenkoE.P. GrishinaE.A. RyzhikovaK.A. TorradoM.V. ShipitsynV.V. BryunE.A. SychevD.A. Impact of CYP2D6 polymorphism on equilibrium concentration of fluoxetine in patients diagnosed with major depressive disorder and comorbid alcohol use disorders.J. Psychiatr. Pract.202127537237910.1097/PRA.0000000000000568 34529603
     [Google Scholar]
  252. CarrollF.I. CarlezonW.A.Jr Development of κ opioid receptor antagonists.J. Med. Chem.20135662178219510.1021/jm301783x 23360448
     [Google Scholar]
  253. WalkerB.M. ValdezG.R. McLaughlinJ.P. BakalkinG. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.Alcohol201246435937010.1016/j.alcohol.2011.10.006 22459870
     [Google Scholar]
  254. KrystalA.D. PizzagalliD.A. SmoskiM. MathewS.J. NurnbergerJ.Jr LisanbyS.H. IosifescuD. MurroughJ.W. YangH. WeinerR.D. CalabreseJ.R. SanacoraG. HermesG. KeefeR.S.E. SongA. GoodmanW. SzaboS.T. WhittonA.E. GaoK. PotterW.Z. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia.Nat. Med.202026576076810.1038/s41591‑020‑0806‑7 32231295
     [Google Scholar]
  255. WatkinsK.E. HunterS.B. BurnamM.A. PincusH.A. NicholsonG. LedaL.S. Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder.Psychiatr. Serv.200556891392610.1176/appi.ps.56.8.913 16088007
     [Google Scholar]
  256. VolkowN.D. Personalizing the treatment of substance use disorders.Am. J. Psychiatry2020177211311610.1176/appi.ajp.2019.19121284 32008390
     [Google Scholar]
  257. McIntyreR.S. LeeY. MansurR.B. Treating to target in major depressive disorder: response to remission to functional recovery.CNS Spectr.201520S1173110.1017/S1092852915000826 26683526
     [Google Scholar]
  258. OpbroekA. DelgadoP.L. LaukesC. McGahueyC. KatsanisJ. MorenoF.A. ManberR. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?Int. J. Neuropsychopharmacol.20025214715110.1017/S1461145702002870 12135539
     [Google Scholar]
  259. PehrsonA.L. CremersT. BétryC. van der HartM.G.C. JørgensenL. MadsenM. HaddjeriN. EbertB. SanchezC. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study.Eur. Neuropsychopharmacol.201323213314510.1016/j.euroneuro.2012.04.006 22612991
     [Google Scholar]
  260. ChenG. NomikosG.G. AffinitoJ. ZhaoZ. Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of ethanol, diazepam, and lithium.Clin. Pharmacokinet.20165591115112710.1007/s40262‑016‑0389‑0 27048210
     [Google Scholar]
  261. OrsoliniL. TomasettiC. ValcheraA. IasevoliF. BuonaguroE.F. FornaroM. FiengoA.L.C. MartinottiG. VellanteF. MatarazzoI. VecchiottiR. PernaG. Di NicolaM. CaranoA. Di BartolomeisA. De GiannantonioM. De BerardisD. Current and future perspectives on the major depressive disorder: Focus on the new multimodal antidepressant vortioxetine.CNS Neurol. Disord. Drug Targets2017161659210.2174/1871527315666161025140111 27781949
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22666240827165327
Loading
Major Depression in Comorbidity with Substance use Disorders: Patients’ Features and Clinical-Neurobiological Rationale of Antidepressant Treatments
Curr. Neuropharmacol. 23, 256 (2025); https://doi.org/10.2174/1570159X22666240827165327
/content/journals/cn/10.2174/1570159X22666240827165327
/content/journals/cn/10.2174/1570159X22666240827165327
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): alcohol use disorder; anhedonia; antidepressants; cognition; Major depressive disorder; personalized treatment; precision psychiatry; substance use disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test